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Abstract
Lung carcinoma development is accompanied by field changes that may have diagnostic significance. We have previously
shown the importance of chromosomal aneusomy in lung cancer progression. Here, we tested whether genomic gains in six
specific loci, TP63 on 3q28, EGFR on 7p12, MYC on 8q24, 5p15.2, and centromeric regions for chromosomes 3 (CEP3) and 6
(CEP6), may provide further value in the prediction of lung cancer. Bronchial biopsy specimens were obtained by LIFE
bronchoscopy from 70 subjects (27 with prevalent lung cancers and 43 individuals without lung cancer). Twenty six biopsies
were read as moderate dysplasia, 21 as severe dysplasia and 23 as carcinoma in situ (CIS). Four-micron paraffin sections were
submitted to a 4-target FISH assay (LAVysion, Abbott Molecular) and reprobed for TP63 and CEP 3 sequences. Spot counts
were obtained in 30–50 nuclei per specimen for each probe. Increased gene copy number in 4 of the 6 probes was
associated with increased risk of being diagnosed with lung cancer both in unadjusted analyses (odds ratio=11, p,0.05)
and adjusted for histology grade (odds ratio=17, p,0.05). The most informative 4 probes were TP63, MYC, CEP3 and CEP6.
The combination of these 4 probes offered a sensitivity of 82% for lung cancer and a specificity of 58%. These results
indicate that specific cytogenetic alterations present in preinvasive lung lesions are closely associated with the diagnosis of
lung cancer and may therefore have value in assessing lung cancer risk.
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Introduction
Early diagnosis of lung cancer is thought to lead to improved
survival. Yet, less then 25% of patients are diagnosed at clinical
stage 1 where expected survival is around 70% at 5 years. This
survival rate is much higher than overall survival in advanced
disease, estimated at 15% at 5 years. Approaches to early diagnosis
of lung cancer remain a major challenge. The onset of the disease
process is extremely slow (months to years) and no means of
evaluating the rate of progression of the disease process are
available.
A variety of lung cancer screening techniques have been studied
to determine their utility in early stage of disease. These include
chest X-ray, sputum cytology and molecular biomarkers in various
biological specimens. None of these early detection strategies has
been found to cause a reduction in cancer-related mortality. Low-
dose spiral computed tomography (CT) may provide an accurate
picture of the anatomic extent of early lung carcinoma [1]. Yet,
although appealing as an early detection strategy, [2,3,4,5,6], the
results of randomized, controlled studies are not known. In
addition, most preinvasive lesions in the central airways will
remain undetected by chest CT.
Molecular detection strategies from airway specimens are
challenging because of the relatively difficult access, paucity of
tissue and lack of molecular changes predictive of cancer. While
the molecular biology of lung cancer has been extensively studied,
no reliable diagnostic molecular correlates exist [7]. Lung cancer
development is characterized by sequential accumulation of
epigenetic and genetic aberrations in somatic cells [8]. These
aberrations include single nucleotide point mutations, changes in
chromosome copy number [9,10], and specific genomic amplifi-
cations or deletions that are implicated in the pathogenesis of lung
tumor development and progression through the activation of
oncogenes and inactivation of tumor suppressor genes
[11,12,13,14,15,16].
Because not all preinvasive lesions develop into invasive tumors,
it is critical to identify molecular determinants driving to an
invasive phenotype [16]. Fluorescence in situ hybridization is
emerging as a potentially useful clinical tool for the assessment of
diagnosis, prognosis, and response to therapy in lung cancer
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closely associated with the diagnosis of lung cancer. Recently we
tested gain in copy numbers of two out of four selected DNA
targets, taken as a reflection of genomic instability and a marker
for risk of lung cancer development [10,23]. In the present study,
we hypothesized that a selected set of cytogenetic alterations in
preinvasive lesions may be a better predictor of lung cancer.
Therefore, we determined whether the results of the cytogenetic
analysis were associated with disease progression in the elected
individuals. We selected six DNA targets commonly amplified in
lung cancer [12,14,15,24,25] including two centromeric probes
(CEP3 and CEP6) and four probes to areas of frequent genomic
amplification, i.e. 3q28 (TP63) [11,13], 5p15.2 (D523 and D5S721
markers) [26], 8q24 (MYC) [27], and 7p12 (EGFR) [28]. With
those validated FISH probes, we performed a quantitative
evaluation of nuclear representation of genomic locus copy
number in preinvasive lesions and their association with a
diagnosis of invasive lung carcinoma.
Materials and Methods
Patient population characteristics
The population included 70 subjects recruited at the University
of Colorado Cancer Center (UCCC), the British Columbia
Cancer Agency (BCCA) and the University of Iceland Hospitals
(UIH). This population represents a subgroup of patients
previously investigated [23] and includes all subjects from that
study with diagnosed moderate dysplasia (4 with lung cancer, 22
controls), severe dysplasia (6 with lung cancer, 15 controls) or
carcinoma in situ (17 with lung cancer, 6 controls), for whom
bronchial sections were available.
The subjects studied were all considered to be at high risk for
lung cancer based on a history of at least 30 pack-years of smoking
and spirometric evidence of airflow obstruction documented by an
FEV1/FVC ration of less than 75% and an FEV1 of less than
70% of predicted. Former smokers were defined as having quit at
least one year before the time of enrollment. Pack-years were
defined as the average number of packs smoked per day multiplied
by the numbers of years smoked. Flexible fiberoptic bronchoscopy
was performed with both autofluorescence and white light
examination of the airways using either a Xillix LIFE II or
OncoLIFE system at the UCCC and BCCA sites; white light
examination alone was performed at the UIH. The BCCA cases
had been diagnosed in a prospective study of early lung cancer
using autofluorescence and white light bronchoscopy or the
subjects were enrolled as part of two National Cancer Institute
sponsored chemoprevention trials. These included 27 patients with
clinical diagnosis of invasive carcinoma (prevalent cases) and 43
subjects who remained free of invasive tumor for at least one year
of follow up (controls). Detailed questionnaire data derived from
personal interview were available on all study subjects, including
demographic characteristics and smoking history. The study was
approved by the local Institutional Review Boards of the
Vanderbilt University, the University of Colorado Health Sciences
Center, the BCCA- University of British Columbia Clinical
Research Ethics Board, the National Bioethics Committee of
Iceland and the Icelandic Data Processing Commission.
Histology and Selection of Areas of Interest
All biopsies obtained at bronchoscopy were scored according to
the most recent WHO classification [29]. Biopsies with diagnoses
ranging from moderate dysplasia to carcinoma in situ were selected
for FISH analysis. Diagnostic areas within individual biopsies were
reviewed and imaged by a pathologist (WAF), who marked the
areas of interest to be specifically examined by FISH.
FISH for CEP3, TP63 (3q28), D523, D5S721 (5p15.2), CEP6,
EGFR (7p12), and MYC (8q24)
Four-micron paraffin sections were initially submitted to a 4-
target FISH assay (LAVysion, Abbott Molecular, Des Moines, IL)
including sequences encompassing the DNA markers D523 and
D5S721 at 5p15.2, centromere 6, the EGFR gene at 7p12 and the
MYC gene at 8q24, according to protocol described elsewhere
[23]. All sections analyzed by FISH were sequential to the
respective H&E section. Individual nuclei were assessed for the
number of fluorescent signal corresponding to a copy number of
the gene of interest. Individual spot counts are referred as signals
separated at least by the size of one fluorescent signal. After the
analysis of these 4 genomic regions, the same sections were
stripped of their fluorescence signals in 70% formamide solution at
72uC for 10 minutes and then re-probed with a 2-target FISH
assay including TP63 at 3q28 (BAC clones RP11-53D15 and
RP11-373I6, digoxigenin-labeled, detected by FITC) and Spec-
trum Orange-CEP 3 sequences (Abbott Molecular, Des Moines,
IL). Immunochemical detection procedures were as described
previously [30].
Hybridized slides were examined in fluorescence microscopes
equipped with proper interference filters and coupled with a
CytoVision Genetic workstation (Applied Imaging). Over the areas
of interest marked by the pathologist, spot counts were obtained
for 30–50 nuclei per specimen for each probe and representative
images captured digitally. Considering that the bronchial sections
had truncated nuclei, for each DNA target the specimen was
defined as abnormal when the mean copy number per cell was
greater than two.
Statistical analysis. We focused first on the distributions of
demographic factors, such as age, sex, smoking status (current or
ex-smoker) and histologic grades. Next, we examined the
differences in mean copy number of each FISH marker based
on the histology. Multiple comparison tests using bootstrap
technique were performed for significance. Third, the
associations between FISH markers and cancer status were
assessed individually and in multiplicity models after controlling
for clinical and biological parameters, such as smoking status and
histology grade, using multiple logistic regression. Associations
were reported as odds ratios with corresponding 95% confidence
intervals (CI). A mean number of #2 copies per nucleus was
considered as the FISH reference value. Finally, we used ROC
analysis (c-statistics) to investigate the contributions of marker
groups in combined models to differentiate cases and controls. All
analyses were carried out in Statistical Analysis Software (Version
9.1, SAS Institute Inc, Cary NC). The comparisons of areas under
the ROC curves between models were examined using the ‘‘ROC
Macro’’ SAS tool [31,32].
Results
Patient clinical information and pathological characteristics of
the lesions are summarized in Table 1. There was no statistical
difference for age, gender, study center and current smoking status
between cases and controls. However, the average smoking
intensity was greater among the cases (pack year (PKY)
mean=80.1, SD=46.1) compared with the controls (mean
PKY=56.6, SD=24.3). Similarly, the distribution of preinvasive
lesions was skewed towards higher grades in patients with cancer.
The mean copy number per cell of selected genomic candidate
biomarkers is reported by case and control status for different
Marker of Risk for Lung Cancer
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increasing in copy number among samples as the histology grade
advances. While the association with histology grade was significant
forTP63,MYC,CEP6,andCEP3(p,0.01),itwasnotforEGFRand
5p15.2. When these relationships were analyzed according to the
proportion of cells that contained more than two copies of each
individual marker, we observed associations limited to these same 4
markers. Interestingly, amplification of sequences was detected in a
total of 8 specimens, for four of the tested targets: TP63, 5p15.2,
EGFR and MYC. Amplificationwasrepresented bysmall to medium
sizeclusters of signals (EGFR)or by more than 50% of cells carrying
more than 5 copies of the signals (MYC, 5p15.2 and TP63).
Representative images are presented in Figure 1.
The percentage of lesions abnormal for each FISH marker
(according to the case or control status), with abnormality defined
as mean copy number per cell greater than two is presented in
Table 3. The presence of a malignancy in the airways was only
moderately associated with the rate of copy number abnormalities
except for MYC, which was more frequently amplified in
preinvasive lesions of patients with lung cancer.
Because access to normal bronchial epithelium from the same
individuals was not possible, moderate dysplasia was used as the
reference baseline to measure the association between copy
number abnormalities and lung cancer status. As shown in
Table 4, the odds of having lung cancer given that a preinvasive
lesion had gain for genomic regions increased from 4.23 (1.21–
14.8, 95%CI) when 1 or 2 markers of 4 (CEP3, TTP63, CEP6,
MYC) were abnormal to 11 (2.63–45.9, 95%CI) when 3 or 4
markers showed elevated copy numbers. Further adjustment for
age, gender, center, current smoking status and histology grade of
the lesion increased the odds to 17.
When assessed as a candidate biomarker signature predictive of
lung cancer, the sensitivity of presence of abnormality in those 4
markers was 82% and specificity was 58%. The receiver operating
characteristic (ROC) curves shown in Figure 2 demonstrate the
added value of histology and epidemiological information,
ultimately achieving an area under the curve of 92.6%. The
demographic information represents gender, age, pack years of
smoking history, and smoking status. The differences between the
curves were significant between demographics vs. demographics
and cytology (p=0.02) or vs. demographics, cytology and 4 FISH
biomarkers (p=0.002). Although showing a trend, the difference
was not significant between demographics and cytology vs.
demographics, histology and 4 FISH biomarkers (p=0.11).
Discussion
Molecular approaches for the early detection for lung cancer
have been targeting the blood, the sputum, the exhaled breath and
bronchial biopsies [7,33]. Preinvasive bronchial lesions are well
established markers of risk and yet the histological grade does not
necessarily predict the outcome [16,34,35]. Our goal was to
determine whether specific genomic alterations in preinvasive
lesions may be predictive of having a lung cancer in high-risk
individuals. While genomic instability was addressed previously
based on a quantitative analysis [23], a more refined molecular
signature is expected to better associate with the diagnosis of lung
cancer. Our results indicate that specific cytogenetic alterations
present in preinvasive lung lesions such as amplification or over-
representation of the TP63 and MYC genes are highly associated
with the diagnosis of lung cancer and therefore suggest a role of
those markers in assessing lung cancer risk. Unlike p53, TP63 is
rarely mutated in lung cancer but a significant fraction of tumor
and premalignant lesions are amplified for both TP63 and MYC
genes.
Although chromosomal alterations have been linked to most
solid tumors and serve as a hallmark of human cancer [36], they
are becoming increasingly complicated; i.e., major patterns are
being diluted by many variants [10,37,38]. Genomic alterations in
Table 1. Distribution of lung cancer cases and controls according to demographic and histology variables.
Characteristics
Individuals with
cancer (Cases, N=27)
Individuals without
cancer (Controls, N=43) Chi-square p value
Gender males 85% 79% 0.75
females 15% 21%
Age 30–59 33% 42% 0.33
60–69 30% 37%
70+ 37% 21%
Study center BCCC 15% 21% 0.34
Iceland 18% 7%
Colorado 67% 72%
Smoking pack-years ,50 37% 56% 0.03
50–74 15% 26%
75+ 41% 14%
unknown 7% 4%
Current smoking yes 70% 58% 0.32
no 26% 37%
unknown 4% 5%
Histologic grade moderate dysplasia, n=26 15% 51% ,0.001
severe dysplasia, n=21 22% 35%
carcinoma in situ, n=23 63% 14%
doi:10.1371/journal.pone.0005611.t001
Marker of Risk for Lung Cancer
PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e5611the airway epithelium occur both stochastically and later in a
clonal manner. Clonal (identical alteration in 2 or more cells) and
non-clonal alterations associated with smoking history participate
in the tumor initiation process. Some alterations may indicate risk
better than others. Thus far, the majority of these alterations have
been considered consequences as opposed to causes in the lung
cancer development. Some of these low level aberrations have
been called random noise but may reflect the measure of true
Figure 1. Dual color fluorescence in situ hybridization of TP63 gene (3q28, green spots) and a CEP3 probe (red spots) on the
centromeric region of the same chromosome on a carcinoma in situ (CIS) of the lung. Interphase nuclei stained in blue with DAPI show
increased copy number of TP63 in CIS (A). Segmented images of 4-color hybridization assays with the LAVysion probe in severe dysplasia lesions,
showing high copy numbers of the 5p15.2 genomic region (green spots) (B); EGFR gene amplification (clustered red spots) (C); and high copy
numbers of MYC (yellow spots) (D). All sections analyzed by FISH were sequential to the H&E section presented.
doi:10.1371/journal.pone.0005611.g001
Table 2. Mean copy number per cell of selected FISH markers by histology grade in bronchial sections of 70 subjects.
Study
Subjects
Histologic
grade N FISH marker (mean copy number and SD per cell)
CEP3 TP63 5p15 CEP6 EGFR MYC
Cases MD 4 1.84(0.05) 1.85(0.08) 3.45(1.77) 1.71(0.18) 2.76(1.17) 2.27(0.51)
SD 6 1.86(0.12) 1.92(0.21) 2.94(1.44) 1.99(0.43) 2.84(1.27) 2.59(1.21)
CIS 17 2.21(0.7) 3.14(1.11) 2.82(0.91) 2.29(0.6) 3.01(2.05) 2.95(0.63)
P value* 0.56 0.04 0.98 0.25 1.00 0.53
Controls MD 22 1.82(0.11) 1.88(0.21) 2.94(1.56) 1.83(0.23) 2.51(1.06) 2.03(0.56)
SD 15 1.93(0.23) 2.12(0.58) 2.4(1.04) 1.75(0.37) 2.59(1.69) 2.03(0.6)
CIS 6 2.02(0.25) 2.74(0.84) 2.21(0.88) 2.08(0.77) 3.25(3.08) 2.3(0.9)
P value* 0.92 0.12 0.88 0.90 0.98 0.98
All MD 26 1.82(0.1) 1.88(0.19) 3.02(1.57) 1.81(0.22) 2.54(1.05) 2.07(0.55)
SD 21 1.91(0.2) 2.06(0.5) 2.55(1.16) 1.82(0.39) 2.66(1.56) 2.19(0.83)
CIS 23 2.16(0.62) 3.04(1.04) 2.66(0.92) 2.23(0.64) 3.07(2.29) 2.78(0.75)
P value* 0.01 ,0.0001 0.86 0.006 0.80 0.003
*ANOVA for differences in mean copy number per cell across the three histology grades.
doi:10.1371/journal.pone.0005611.t002
Marker of Risk for Lung Cancer
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defective mitotic figures, chromosomal fragmentation, missegrega-
tion or non-recurrent genomic alterations indicate a dynamic
process leading to instability [39]. In this study, we found that the
high frequency of non-coding centromeric alterations (CEP3 and
CEP 6) was independently associated with a diagnosis of lung
cancer (Table 2), and therefore although not specifically linked to
tumorigenesis, it is probably part of the genomic instability coming
along with the disease process.
In contrast, specific genomic amplifications or deletions
[12,15,40] have been implicated in the pathogenesis of tumor
development in part through the activation of oncogenes [41] and
inactivation of tumor suppressor genes. Some genomic signatures
seem to persist after tumor development, throughout their
progression [42] and their histology differentiation. Preinvasive
lesions have shown copy number alterations for several chromo-
somal regions including 3q28, 5p15 and 8q24 [10,13,23,43,44]
and these alterations were also found. Genomic imbalances have
been extensively investigated in invasive NSCLCs using CGH or
SNP array methodology and numerous loci were found commonly
amplified or over-represented in either or both squamous and
adenocarcinoma of the lung [14,15,24,25,45,46,47,48,49]. If some
of them are demonstrated to be early events, this may improve the
test performance in the context of diagnosis of lung cancer.
We hypothesized that genomic alterations in TP63, 5p15.2,
EGFR, MYC, CEP 6 and CEP 3, may provide a measure of risk
assessment. Increased copy number (over-representation or
amplification) is technically more reliable to detect with fewer
false positives than genomic loss, mainly when using FISH assay in
sectioned specimens exhibiting nuclear truncation, thus we have
focused on loci that were involved in genomic gain. The cut off for
‘‘normal’’ copy number gain was set at #2 copies per nucleus
based on the fact that the normal disomic cells have two copies of
each genomic target and these cells were sectioned at 4 mm, which
generated truncated nuclei. Although this value may not be the
optimal cut off to use, it is conservative and assures that samples
classified as exhibiting genomic gain are actually abnormal.
TP63 is an appealing target located at the tip of one of the most
prevalent region of amplification in lung cancer. TP63 is a
homologue of p53, which plays a role in development and
oncogenesis by regulating proliferation and differentiation. Interest
in TP63 stems from this ‘‘two genes in one’’ concept with agonist
and antagonist properties that may be involved in tumor
development [50]. TP63 is a complex gene that has multiple
transcriptional isoforms, some of which are tumor suppressors (the
TP63 isoforms), while the others are oncogenes (DTP63;d N TP63)
[11].The TATP63 isoforms can bind to DNA through p53-
responsive elements and therefore ‘‘p53-like’’. The DNTP63 exerts
dominant negative effects over p53 and is proposed as oncogenic.
We found that there is an early and frequent genomic
amplification of TP63 in the development of squamous carcinoma
of the lung and that patients with NSCLC showing amplification
and overexpression of TP63 have prolonged survival [13]. The
DNTP63a splice variant is the most commonly expressed isoform
in squamous epithelia [11,13]. The oncogenic activity of the TP63
isoforms may explain why we see the amplification and
overexpression of this protein. MYC is also an important oncogene
in lung cancer. It is expressed in a large number of NSCLCs [51].
Gene amplification at 8q24 and resultant increased expression of
MYC is a common occurrence in carcinomas [48,52,53]. It leads to
Table 3. Percentage of lesions with abnormal FISH copy numbers according to case or control status (70 subjects).
Study Subjects
Mean copy
number per cell FISH marker
CEP3 TP63 5p15 CEP6 EGFR MYC
Cases (n-27) #2 copies 67% 48% 33% 63% 30% 26%
.2 copies 33% 52% 67% 37% 70% 74%
Controls (n=43) #2 copies 84% 72% 53% 84% 53% 77%
.2 copies 16% 28% 47% 16% 47% 23%
Unadjusted OR 2.57 2.78 2.3 3.02 2.73 9.42
(95% CI) (0.82–8.02) (1.01–7.61) (0.84–6.24) (0.98–9.31) (0.98–7.57) (3.09–28.72)
Adjusted* OR 3.2 4.17 2.66 3.55 3.08 13.08
(95% CI) (0.72–14.11) (0.91–19.00) (0.90–7.93) (1.06–11.86) (1.01–9.33) (3.45–49.48)
*Adjusted by multiple logistic regression for gender, age, center, and current smoking status.
doi:10.1371/journal.pone.0005611.t003
Table 4. Association between disease status and abnormal FISH marker (.2 copies per cell) for the top 4 markers (CEP3, TP63,
CEP6, MYC).
Number of abnormal FISH markers
among the top 4 Lung cancer cases Controls Unadjusted OR (95% CI) Adjusted OR* (95% CI)
0 18% 58% 1.00 (reference) 1.00 (reference)
1–2 41% 30% 4.23 (1.21–14.8) 4.45 (0.84–23.6)
3–4 41% 12% 10.99 (2.63–45.9) 16.97 (1.47–195.0)
*Adjusted by multiple logistic regression for gender, age, center, current smoking status and histologic grade.
doi:10.1371/journal.pone.0005611.t004
Marker of Risk for Lung Cancer
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factors that alter gene expression in large part by recruiting
histone-modifying enzymes [47].
Our data suggest that the changes observed for 5p15 and EGF R
were less predictive of cancer, but these changes seemed to happen
earlier in the dysplastic process, at least in smokers. Among 20
bronchial specimens with normal histology from never smokers,
none have elevated EGFR or 5p15 copy number. Average copy
number for these 20 specimens were 1.77 (STD 0.53) for EGFR
and 1.73 for 5p15 [10]. These observations are also consistent with
the observation of frequent EGFR mutations (24–43%) found in
the airway epithelium in the vicinity of tumors [54,55], and with
the data showing frequent early events on 5p in squamous
differentiation of lung cancer [55,56].
Our design included controls who did not present with lung
cancer for at least 12 months after endobronchial biopsy. Since
genomic instability occurs not only among cases but also among
controls, some of these high-risk controls may eventually develop
lung cancer later and our cross sectional study design does not
address this risk. Other limitations of the study include the nature
of the tissues examined, a relative small sample size (although the
study of 70 fully annotated high grade preinvasive lesions required
three centers and is one of the largest reported to date), and the
inability to study these samples’ progression over time.
The use of bronchial biopsies for assessment of lung cancer risk
is unlikely to be of optimal clinical use, although it may be useful to
predict future cancer in subjects who happen to undergo a biopsy
showing high grade bronchial preneoplasia. This type of molecular
analysis may have to move to surrogate tissue in the airways
including the histologically normal airway epithelium. The small
size of the preinvasive lesions and the potential therapeutic effect
of biopsies make the evaluation of the progression rate of the
aberrations in these tissues rather challenging. Cross-sectional
studies allow the investigation of the association between
alterations and disease state. Yet, to prove clinical utility, the
candidate biomarkers will require further validation in prospective
cohort studies.
The accuracy of our cytogenetic signature may be improved in
different ways. Genome wide copy number alterations of invasive
and preinvasive lesions may allow the selection of regions more
specifically associated with the diagnosis of lung cancer. Increasing
the number of targets studied in small tissue samples is challenging
but newer technologies may help reach this goal. Ultimately,
refining a genomic signature observed in preinvasive lesions that
predicts who is likely to develop lung cancer would be very
informative. In this context, repeated measurement of such
alterations and the rate of its accumulation may be particularly
valuable in predicting the likelihood of developing lung cancer.
In this study we took advantage of advances in lung cancer
molecular genetics and demonstrated that there is a strong
association between targeted genomic alterations in preinvasive
bronchial lesions and the diagnosis of lung cancer. These alterations
can be reliably assessed by FISH, and may represent a method to
measure the risk of developing lung cancer. The predictive value of
thesealterationsdeservesfurtherevaluationintheairwayepithelium
of high risk individuals in longitudinal studies.
Figure 2. Receiver operating characteristic curves describing the diagnostic prediction accuracy of three models, demographics
alone (plain line, area under the curve (AUC) 73.4%), in combination with cytology (dashed line, AUC 86.6%) or demographics in
combination with cytology and 4 FISH biomarker candidates (dotted line, AUC 92.6%). The demographic information represents gender,
age, pack years smoking history, and smoking status.
doi:10.1371/journal.pone.0005611.g002
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